Codexis to Participate in Piper Sandler 34th Annual Healthcare Conference
16. November 2022 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management...
Codexis to Participate in Upcoming Healthcare Conferences
08. November 2022 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management...
Codexis Reports Third Quarter 2022 Financial Results
03. November 2022 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced financial...
Codexis Announces Appointment of Margaret Fitzgerald as Chief Legal Officer and General Counsel
01. November 2022 08:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment...
Codexis to Report Third Quarter 2022 Financial Results on November 3
20. Oktober 2022 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will...
Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors
03. Oktober 2022 08:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment...
Codexis Announces Appointment of Kevin Norrett as Chief Operating Officer
03. Oktober 2022 08:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment...
Codexis’ 2022 Protein Engineering Forum Showcases Recent Industry Success and Emerging Innovations in the Field
14. September 2022 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the recent...
Codexis Reports Second Quarter 2022 Financial Results
04. August 2022 16:05 ET
|
Codexis, Inc.
Total Revenue up 51% and Product Revenue up 135% YOY 2022 Total Revenue Guidance of $135M-$141M, Including Product Revenues of $112M-$118M REDWOOD CITY, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) --...
Codexis and Molecular Assemblies Announce Execution of Commercial License and Enzyme Supply Agreement for Optimized TdT Enzyme for Enzymatic DNA Synthesis
02. August 2022 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif. and SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Molecular...